­Nevro to Participate in Citi Bank Head Shoulders Knees and Toes Conference Call Series on November 30th

Rhea-AI Summary

Nevro Corp. (NYSE: NVRO), a leader in innovative medical devices for chronic pain, announced that CEO D. Keith Grossman will participate in Citi Bank's Head Shoulders Knees and Toes Conference Call Series on November 30, 2020, at 2 pm ET. Investors can join the call by dialing (856) 344-9142 with Conference ID: 3168278. Nevro's Senza spinal cord stimulation system has shown success in reducing opioid use in over 65% of patients, highlighting its effectiveness in chronic pain treatment. For more details, visit www.nevro.com.

News Market Reaction – NVRO

-0.11%

-0.11% Session move

In the trading session that priced this news, NVRO declined 0.11%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Nov. 24, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President will participate in Citi Bank's Head Shoulders Knees and Toes Conference Call Series on November 30, 2020 at 2pm ET.

Investors interested in listening to the call may do so by dialing (856) 344-9142 in the U.S., using Conference ID: 3168278. This dial-in information is available on the "Investors" section of the Company's website at: www.nevro.com.

About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza^® System, Senza II™ System, and the Senza^® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10^® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investor Relations:
Matt Bacso, CFA
ir@nevro.com

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-to-participate-in-citi-bank-head-shoulders-knees-and-toes-conference-call-series-on-november-30th-301179492.html

SOURCE Nevro Corp.

FAQ

What conference call will Nevro participate in on November 30, 2020?

Nevro will participate in Citi Bank's Head Shoulders Knees and Toes Conference Call Series.

Who is the speaker for Nevro in the conference call on November 30?

D. Keith Grossman, Nevro's Chairman, CEO and President will be the speaker.

How can I listen to Nevro's conference call on November 30, 2020?

Investors can listen by dialing (856) 344-9142 and using Conference ID: 3168278.

What is Nevro's stock symbol?

Nevro's stock symbol is NVRO.

What innovative product does Nevro offer for chronic pain treatment?

Nevro offers the Senza spinal cord stimulation system as an innovative solution for chronic pain.